POA Pharma is now a Galen company

Galen, the privately owned global pharmaceutical sales and marketing company, is delighted to announce the acquisition and takeover of boutique healthcare company, POA Pharma.

New website coming soon

  • POA Pharma Scandinavia AB signs distribution agreement with Darou Darman Kian Co. Iran.

    POA Pharma Scandinavia AB signs distribution agreement with Darou Darman Kian Co for marketing and sale of POA Pharma´s metabolic product portfolio, Inborn Errors of Metabolism and the Antisecretory Factor – SPC Flakes® and Salovum® in Iran.

    ”The market for products defined as Medical Nutrition is a highly competitive but fast growing market all over the world. POA intends to be among the leading companies and adding Iran, were Phenylketonuria (PKU) with an incidence estimated at 1 in 3,627 live births  to our geographic presence, opens very interesting possibilities for the future. We are very happy signing with with Darou Darman Kian C. for this exiting market,  says Tina Madsen Sandsträm, CEO of POA Pharma.

    POA Pharma Scandinavia AB also includes in it´s partnership with Darou Darman Kian C also the Antisecretory Factor – SPC Flakes® and Salovum® Antisecretory Factor (AF) is a protein secreted in plasma and tissue fluids in mammals. Immunocytochemistry has shown that AF is present in most tissues. The endogenous plasma level of AF is increased by enterotoxins and surprisingly also by certain food constituents. Based on these findings, AF inducing medical food have been developed. SPC Flakes® is an AF-inducing medical food and Salovum®  (B221) an AF-rich egg yolk powder.

    Clinical trials in Crohn´disease and short bowel syndrome has shown that AF exerts both antisecretory effects and anti-inflammatory effects. Because of the effects on hypersecretion in the GI tract it was hypothesized that AF treatment could be valuable in other instances were fluid balance is thought to play a role, such as Ménière´s disease. This has been proven in four published studies out of them two are double blinded and one a cross-over trial.

    About Darou Darman Kian C: “Darou Darman Kian Co. who has been in Iran market since 2011 is exclusively focus on importing pharmaceutical and healthcare products into Iran Pharmaceutical market.                                                                                                              Darou Darman Kian’s mission is to become a leader pharmaceutical company through the introduction of a wide portfolio of branded products in one of the world’s key markets like Iran.We are strongly committed to provide high quality products to improve the quality of life of patients. Our vision is to explore newer products and newer markets. Through our expertise, we pursue opportunities on behalf of patients facing disease to offer essential medicines and provide physicians and patients right choices for treatment which requires bold leaders.”

    About POA Pharma – The Boutique Healthcare Company: POA Pharma is a market oriented Boutique Healthcare Company present in 9 competence areas with offices in Denmark, Finland, Norway, Sweden and US. The home Market is the Nordic countries were POA represents 12 Pharmaceutical producers from 10 countries. Our export is based on POA proprietary products, classified as Food for specific medical Purposes, products that are sold in more than 40 countries.

    Leave a reply →